- Home
- CRBU vs AVIR Comparison
CRBU vs AVIR Comparison
Compare CRBU & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- AVIR
- Stock Information
- Founded
- CRBU 2011
- AVIR 2012
- Country
- CRBU United States
- AVIR United States
- Employees
- CRBU N/A
- AVIR N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CRBU Health Care
- AVIR Health Care
- Exchange
- CRBU Nasdaq
- AVIR Nasdaq
- Market Cap
- CRBU 236.3M
- AVIR 276.9M
- IPO Year
- CRBU 2021
- AVIR 2020
- Fundamental
- Price
- CRBU $2.00
- AVIR $3.37
- Analyst Decision
- CRBU Strong Buy
- AVIR Hold
- Analyst Count
- CRBU 3
- AVIR 1
- Target Price
- CRBU $14.00
- AVIR $6.88
- AVG Volume (30 Days)
- CRBU 1.9M
- AVIR 181.4K
- Earning Date
- CRBU 11-06-2024
- AVIR 11-07-2024
- Dividend Yield
- CRBU N/A
- AVIR N/A
- EPS Growth
- CRBU N/A
- AVIR N/A
- EPS
- CRBU N/A
- AVIR N/A
- Revenue
- CRBU $11,475,000.00
- AVIR N/A
- Revenue This Year
- CRBU N/A
- AVIR N/A
- Revenue Next Year
- CRBU N/A
- AVIR N/A
- P/E Ratio
- CRBU N/A
- AVIR N/A
- Revenue Growth
- CRBU N/A
- AVIR N/A
- 52 Week Low
- CRBU $1.50
- AVIR $2.81
- 52 Week High
- CRBU $8.33
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- CRBU 43.48
- AVIR 50.67
- Support Level
- CRBU $2.37
- AVIR $3.10
- Resistance Level
- CRBU $2.08
- AVIR $3.48
- Average True Range (ATR)
- CRBU 0.26
- AVIR 0.13
- MACD
- CRBU -0.07
- AVIR -0.00
- Stochastic Oscillator
- CRBU 6.42
- AVIR 52.38
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).